Arizona Oncology - The US Oncology Network

ARIZONA ONCOLOGY EXPANDS FLAGSTAFF PRACTICE TO MEET GROWING DEMAND FOR SERVICES IN NORTHERN ARIZONA: Demand for Cancer-Related Services to Increase as Flagstaff Population Grows 17.7 percent by 2020

2/16/2015

Flagstaff, Ariz. (February 16, 2015)—Arizona Oncology, a practice in The US Oncology Network, has expanded its Flagstaff clinic location to meet the growing demand for cancer treatment services in Northern Arizona.
Paul Kuefler, M.D. is pleased to announce that Peter Mathern, M.D. is joining him in a full-time capacity at the Arizona Oncology clinic location on 1329 N. Beaver Street. Both specialize in hematology and medical oncology and will work together to meet the growing demand for cancer treatment services in Flagstaff and the surrounding areas.
 

According to the 2012 Flagstaff Regional Plan, the population of Flagstaff is projected to hit 77,500 (17.7 percent increase) by the year 2020. Coupled with an increase in visitors to the area, the potential number of people potentially in need of cancer-related services increases to a population of 2.7 million.
 

“We pride ourselves in delivering the best patient care possible,” says Dr. Mathern. “To stay ahead of the curve and ensure that our patients continue to be seen by a physician in a timely manner and receive the necessary attention and care, now is the time for us to expand the team in Flagstaff.”
 

Dr. Mathern is originally from Kosice, Czechoslovakia. A former captain in the Czechoslovak Army, before pursuing a medical career, Dr. Mathern was a nationally syndicated radio reporter for the Czechoslovak National Broadcast Co., a film critic and a downhill skiing instructor.
In addition to specializing in oncology and hematology, he has extensive experience in general practice as an internist at the University of Nevada Medical Center QuickCare Clinic in Laughlin, Nevada, and at the Mohave Valley Hospital and Medical Center in Bullhead City, Arizona.
Dr. Mathern attended medical school at the Charles University Medical School in Prague, Czechoslovakia, completed his residency at Vanderbilt University Medical Center in Nashville, Tennessee, and completed his fellowship at Boston University Medical Center in Boston, Massachusetts. His research has been widely published in journals including Journal of Clinical Immunology, Cytogenetics and Cell Genetics, Journal of Immunology, Pediatric Research and Journal of Neuroimmunology.
 

To learn more about the new team of Drs. Peter Mathern and Paul Kuefler at the Arizona Oncology Flagstaff clinic location, visit ArizonaOncology.com or call at 855-234-HEAL(4325).
 

About Arizona Oncology
Arizona Oncology is one of the largest medical groups in Arizona. With more than 60 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic, and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Chandler, Cottonwood, Deer Valley, Flagstaff, Glendale, Green Valley, Nogales, Oro Valley, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson.
 

Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit ArizonaOncology.com.
 

Arizona Oncology is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. As an affiliate of The US Oncology Network, Arizona Oncology is united with 1,000 physicians nationwide. Arizona Oncology participates in clinical trials through US Oncology Research, which has played a role in 52 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.